Results 41 to 50 of about 8,165 (189)

Crucial involvement of xanthine oxidase in the intracellular signalling networks associated with human myeloid cell function [PDF]

, 2014
Xanthine oxidase (XOD) is an enzyme which plays a central role in purine catabolism by converting hypoxanthine into xanthine and then further into uric acid.
Abooali, Maryam, Coughlan, Karen, Gibbs, Bernhard F., Lall, Gurprit S., Lall, Harjinder S., Sumbayev, Vadim V.   +5 more
core   +1 more source

Improvements in Health-Related Quality of Life With Treat-to-Target Urate-Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial. [PDF]

Arthritis Care Res (Hoboken)
Objective Although treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL ...
Barry A, England BR, Sayles H, Helget LN, Androsenko M, Wu H, Michaud K, Kramer B, Newcomb JA, Brophy MT, Davis-Karim A, Ferguson R, Pillinger MH, Neogi T, Palevsky PM, O'Dell JR, Mikuls TR.   +16 more
europepmc   +2 more sources

Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants? [PDF]

, 2015
BACKGROUND: Patient recruitment into clinical trials is a major challenge, and the elderly, socially deprived and those with multiple comorbidities are often underrepresented.
BC Martinson, BS Frey, CL Tishler, Claudine G Jennings, E Jones, EJ Emanuel, H Draper, IS Mackenzie, Isla S Mackenzie, J Saunders, JC Wong, Lewis McConnachie, Li Wei, Morris J Brown, N Dickert, PA Rochon, RM Titmuss, S Treweek, SD Halpern, Thomas M MacDonald, TM MacDonald   +20 more
core   +3 more sources

(Poly)Borylated Species as Modern Reactive Groups toward Unusual Synthetic Applications

Angewandte Chemie, Volume 138, Issue 10, 2 March 2026.
In this review, we spotlight recent breakthroughs in α‐polyboron‐substituted carbon‐centered intermediates (carbanion, carbocation, radical, and carbene) and polyborylated alkenes. By bridging fundamental reactivity with the application potential of these extraordinary species, we hope this review will serve as a roadmap for harnessing these unique ...
Nadim Eghbarieh, Nicole Hanania, Pinaki Nad, Tipu Alam, Tamir Kish, Ahmad Masarwa   +5 more
wiley   +2 more sources

Does the provision of a DVD-based audio-visual presentation improve recruitment in a clinical trial? A randomised trial of DVD trial invitations [PDF]

, 2019
Background Recruitment to clinical trials can be challenging. Methods that improve the efficiency of trial recruitment are needed to increase successful study completions.
Flynn, Robert, MacDonald, Thomas, Mackenzie, Isla, Rogers, Amy   +3 more
core   +4 more sources

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients

Renal Failure, 2019
The aim of this study was to evaluate the efficacy and tolerability of febuxostat in renal transplant recipients who were previously treated with allopurinol (the daily oral dose is 100 mg).
Yanchun Li, Min Liu, Xuelei Zhang, Yuewu Lu, Juan Meng   +4 more
doaj   +1 more source

A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated With Colchicine Prophylaxis

Arthritis &Rheumatology, EarlyView.
Objective This study investigated that serum metabolomics, before urate‐lowering therapy (ULT) initiation, could serve as a biomarker for responsiveness to colchicine prophylaxis in patients with gout commencing treat‐to‐target ULT. Methods We studied a multicenter prospective cohort (n = 409) initiating treat‐to‐target ULT plus colchicine prophylaxis.
Wenyan Sun, Lingfang Xu, Haibing Chen, Mingshu Sun, Zhiqiang Li, Rui Li, Lidan Ma, Hui Zhang, Aichang Ji, Yuwei He, Na Wu, Le Yan, Robert Terkeltaub, Changgui Li   +13 more
wiley   +1 more source

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study

Scientific Reports, 2022
Attribute-based medicine is essential for patient-centered medicine. To date, the groups of patients with chronic kidney disease (CKD) requiring urate-lowering therapy are clinically unknown.
Hiroshi Kataoka, Toshio Mochizuki, Mamiko Ohara, Yuki Tsuruta, Naomi Iwasa, Rie Yoshida, Ken Tsuchiya, Kosaku Nitta, Kenjiro Kimura, Tatsuo Hosoya, the FEATHER Investigators   +10 more
doaj   +1 more source

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. [PDF]

, 2019
ObjectiveLesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI. The aim of the study was
Baumgartner, Scott, Goldfarb, David S, Jalal, Diana, Pillinger, Michael, Saag, Kenneth G, Schechter, Bruce M, Terkeltaub, Robert, Valiyil, Ritu, White, William B   +8 more
core   +1 more source

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy [PDF]

, 2013
INTRODUCTION: Two replicate randomized, placebo-controlled six-month trials (RCTs) and an open-label treatment extension (OLE) comprised the pegloticase development program in patients with gout refractory to conventional therapy.
Baraf, Herbert SB, Becker, Michael A, Gutierrez-Urena, Sergio R, NC DOCKS at East Carolina University, Ottery, Faith D, Rehrig, Claudia D, Sundy, John S, Treadwell, Edward L, Vazquez-Mellado, Janitzia, Yood, Robert A   +9 more
core   +2 more sources